-
Jan 17, 2025 | 
mdpi.com | Wei Lu |Yu Zou |Xingyu Luo |Jun Song
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Jan 16, 2025 | 
mdpi.com | Jun Song |JunRu Guo |Yanzhao Fu |Lingxiang Yao
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Jan 7, 2025 | 
mdpi.com | Jun Song |Shuai Ye |Minghao Kang |Shujian Ji
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Dec 2, 2024 | 
cozen.com | Andrew Stewart |Jun Song |Manveer Sall
Monday, December 2, 2024
Vancouver, BC, December 2, 2024 – Cozen O’Connor LLP announced that it represented Aduro Clean Technologies Inc. (NASDAQ: ADUR; CSE: ACT; FSE: 9D5), a clean technology company using the power of chemistry to transform lower value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, in its $4 million U.S. initial public offering and Nasdaq listing.
-
Nov 29, 2024 | 
mdpi.com | Jun Song |Caitlin Martin
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Oct 25, 2024 | 
preprints.org | Jun Song |Poornima Lakshini Kumbukgahadeniya |Warisraporn Tangchang |Gi Young Jung
Preprint Case Report Version 1 This version is not peer-reviewed Version 1 : Received: 25 October 2024 / Approved: 25 October 2024 / Online: 25 October 2024 (13:27:32 CEST) Tangchang, W.; Jung, G. Y.; Song, J. Y.; Kumbukgahadeniya, P.; Kwon, H. J.; Son, H.-Y. Endocrine Mucin-Producing Sweat Gland Carcinoma (EMPSGC) in a Dog: Immunohistochemical Characterization and Diagnostic Approach. Preprints 2024, 2024102030. https://doi.org/10.20944/preprints202410.2030.v1 Tangchang, W.; Jung, G. Y.; Song, J.
-
Sep 29, 2024 | 
mdpi.com | Yong Tang |Yidan Lu |Benyuan Ma |Jun Song
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Sep 24, 2024 | 
onlinelibrary.wiley.com | Yujiro Yamada |William B. Hammert |Ryo Kataoka |Jun Song
DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author, [JPL], upon reasonable request.
-
Sep 17, 2024 | 
bmccancer.biomedcentral.com | Yujie Deng |Xiaohui Chen |Xuzheng Chen |Zhiguang Zhang |Zhenguo Xu |Xiurong Wang | +4 more
Clinical samples from 43 stage I LUAD patients from Fujian Cancer Hospital between January 2010 and July 2011 were included in this retrospective study. The study protocol was approved by the Human Ethics Review Committee of Fujian Medical University Cancer Hospital (SQ2021-101–01), and a signed informed consent was obtained from each patient. None of the patients had received chemotherapy or radiotherapy prior to surgery, and the final follow‐up was updated until death or February 2021.
-
Sep 12, 2024 | 
mdpi.com | Tiffany Tse |Hoyoung Jung |Mohammad Shahidul Islam |Jun Song
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
